Jean-Charles Wirth and Danny Bar-Zohar are set to assume the life science and healthcare CEO roles respectively.

Peter Guenter will retire as CEO of Merck KGaA’s healthcare business on June 1, one of several personnel moves that the German pharma announced earlier ...

Germany's Merck KGaA said on Tuesday its lab equipment division and its pharmaceuticals division would be under new ...

Merck Foundation Chief Executive Officer (CEO) advanced Cancer Care in Africa by providing 194 Oncology Scholarships in ...

Gilead Sciences has defied analysts’ expectations by passing on its chance to license Arcus Biosciences’ potential rival to Merck & Co.’s kidney cancer drug Welireg.

After a slow 2024, dealmaking in the U.S. healthcare sector is picking up. Springworks has a market value of $3 billion.

Investors are undervaluing promising drug candidates on the horizon for the two pharma giants, write Yale SOM’s Jeffrey Sonnenfeld and co-author Steven Tian.

Inhibikase Therapeutics (IKT) appointed Mark Iwicki as the company’s CEO, replacing Milton Werner, founder of Inhibikase, effective February ...

2) Merck’s Pipeline of Drugs Is Worth More Than $50 Billion In its Q4 conference call, Merck CEO Rob Davis stated they have 20 potential new pipeline treatment growth drivers, almost all of ...

Big Tech and pharmaceutical companies are accelerating the implementation of artificial intelligence in the healthcare ...